Friday, January 21

Johnson & Johnson, Sinopharm and Sputnik V vaccines are the least effective against omicron


The Covid-19 vaccines of the American pharmaceutical company Johnson & Johnson and from china Sinopharmas well as the Russian injection Sputnik V, had no neutralizing activity against the omicron variant, according to one study.

The study – carried out by Humabs Biomed, a unit of Vir Biotechnology, and the University of Washington, among others – compared the activity of some widely used Covid-19 vaccines and treatments against omicron and against the original strain of the virus first detected in China.

Vaccines Moderna, Astrazeneca, Pfizer and their partner Biontech they maintained activity against omicron, but the antibody response was significantly reduced compared to the original strain, according to the study.

The decline was also found to be less pronounced in vaccinated individuals who had been previously infected.

Unrepresentative serum samples

The Gamaleya Center of Russia issued a statement stating that the Sputnik V vaccine was “deliberately tested using serum samples that are not representative” and that therefore no conclusions could be drawn about its efficacy against the omicron variant based on the study.

The Russian Fund for Direct Investment said Friday that the vaccine induces a “robust neutralizing” antibody response against the omicron variant, citing a preliminary laboratory study from the Gamaleya Center.

The Humabs Biomed study also found that, while the efficacy of the Covid-19 drug sotrovimab from GlaxoSmithKline and Vir Biotech was reduced three times against omicron compared to the original strain, monoclonal antibody treatments of Regeneron y Eli Lilly they completely lost their neutralizing activity against the variant.

The finding is consistent with recent laboratory tests showing that the two treatments lose most of their efficacy when exposed to the omicron variant.

In a real-world study published this week, Pfizer-Biontech’s Covid-19 vaccine has been found to be less effective in South Africa in keeping people infected with the virus out of the hospital since the omicron variant appeared last month. .



www.finanzas.com